

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



February 6, 2026

Company name: Mochida Pharmaceutical Co., Ltd.  
Name of representative: Naoyuki Mochida, Representative Director, President  
(Securities code: 4534)  
Inquiries: Kenichi Miyamoto, Head of Finance & Accounting Department  
(Telephone: +81-3-3358-7211)

## Notice Concerning Revisions to Full-Year Consolidated Financial Results Forecasts

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces that in light of the most recent operating trends, it has decided to revise the financial results forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026), disclosed with the announcement of financial results on May 12 last year, as described below.

### 1. Revisions to consolidated financial results forecasts for the fiscal year (from April 1, 2025 to March 31, 2026)

	Consolidated net sales	Consolidated operating profit	Consolidated ordinary profit	Profit attributable to owners of parent	Consolidated earnings per share
Previously announced forecasts (A)	Millions of yen 110,500	Millions of yen 7,000	Millions of yen 7,500	Millions of yen 5,400	Yen 152.33
Revised forecasts (B)	115,500	9,500	11,000	8,400	236.95
Change (B-A)	5,000	2,500	3,500	3,000	
Change (%)	4.5	35.7	46.7	55.6	
(Reference) Actual consolidated results for the previous fiscal year (Fiscal year ended March 31, 2025)	105,159	8,126	8,067	5,685	160.36

### 2. Reason for revision

Regarding the full-year financial results forecasts, the pharmaceutical business has continued to perform steadily, and net sales and operating profit are now expected to exceed the previously announced forecast. In addition, mainly due to equity-method investment income, ordinary profit and profit attributable to owners of parent are also expected to surpass the earlier forecast.

In light of the above, the Company has revised upward its consolidated financial results forecasts for the full year, previously announced on May 12, 2025, for net sales, operating profit, ordinary profit, and profit attributable to owners of parent, as described above.

\* The above financial results forecasts have been prepared based on information available to the Company as of the date of this announcement. Actual results may differ from the above forecast figures due to various factors in the future.